clinical trial · NCT04884243
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
Cloudbreak Therapeutics, LLC·phase2·completed·n = 92
Meibomian Gland DysfunctionCBT-006
brief summary
STUDY DESIGN Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study. Duration: 3 months of TID treatment. Treatment Groups, Dosing, and Treatment Regimen: Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle
started
Sep 5, 2021
primary completion
Aug 17, 2023
completion
Aug 17, 2023
last updated
Apr 24, 2024
detailed description
Structure:
Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.
Duration:
3 months of TID treatment.
Treatment Groups, Dosing, and Treatment Regimen:
Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle
official title
A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol